Clinical Significance of Serum Vascular Endothelial Growth Factor and Complement 3a Levels in Patients with Colorectal Cancer in Southern Iran |
Mehrabani, Davood
(Stem Cell and Transgenic Technology Research Center, Department of Pathology, Shiraz University of Medical Sciences)
Shamsdin, Seyedeh Azra (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences) Dehghan, Alireza (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences) Safarpour, Alireza (Gastroenterohepatology Research Center, Shiraz University of Medical Sciences) |
1 | Ahluwalia A, Jones MK, Matysiak-Budnik T, et al (2014). VEGF and colon cancer growth beyond angiogenesis: Does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism? Current Pharmaceutical Design, 20, 1041-4. DOI |
2 | Ahluwalia A, Jones MK, Szabo S, et al (2013). Ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism. Biochem Biophys Res Commun, 437, 515-20. DOI |
3 | Cetin B, Kaplan MA, Berk V,et al (2012). Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factortargeting agents. Asian Pac J Cancer Prev, 13, 1059-63. DOI |
4 | Cunningham D, Atkin W, Lenz IJ, et al (2010). Colorectal cancer, Lancet, 375, 1030-47. DOI ScienceOn |
5 | Dube C, Rostom A, Lewin O, et al (2007). US Preventive Services Task Force: The use of aspirin for primary prevention of colorectal cancer: A systemic review prepared for the US Preventive Services Task Force. Ann Int Med, 146, 365-75. DOI |
6 | Enewold L, Horner MJ, Shriver CD (2014). Socioeconomic disparities in colorectal cancer mortality in the United States, 1990-2007. J Community Health, 39, 760-6. DOI |
7 | Fauci A, Rasper D, Longo D, et al (2008). Harissons Principles of Internal Medicine. Seventeenth edition. New York: McGraw Hill. |
8 | Ferlay J, Bray F, Pisani P, et al (2011). Cancer Incidence, Mortality and Prevalence Worldwide. GLOBOCAN, IARC Cancer Base, 5. version 2.0. http://www-dep.iarc.fr/ Accessed 10 July. |
9 | Greene FLPD, Fleming ID, Fritz A (2002). AJCC Cancer Staging Manual. 6th ed., New York: Springer; p. 421. |
10 | Habermann JK, Roblick UJ, Luke BT, et al (2006). Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology, 131, 1020-9. DOI ScienceOn |
11 | Kanmura S, Uto H, Sato Y, et al (2010). The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol, 45, 459-67. DOI |
12 | Levin B, Brooks D, Smith RA, et al (2003). Emerging technologies in screening for colorectal cancer: CT colonography. immunochemical fecal occult blood test and stool screening using molecular markers. CA Cancer J Clin, 53, 44-5. DOI ScienceOn |
13 | Kara O, Duman BB, Kara B, et al (2012). Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev, 13, 6397-401. 과학기술학회마을 DOI |
14 | Kargi A, Yalcin AD, Erin N, et al (2012). Erratum to IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer. Clin Lab, 58, 1103-7. |
15 | Kyutoku M, Nakagami H, Koriyama H, et al (2013). Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep, 3, 3380. |
16 | Lieberman DA, Weiss DG, Bond JH, et al (2000). Use of colonoscopy to screen asymptomalic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med, 343, 162-8. DOI ScienceOn |
17 | Lowery JT, Horick N, Kinney AY, et al (2014). A randomized trial to increase colonoscopy screening in members of high risk families in the Colorectal Cancer Family Registry and Cancer Genetics Network. Cancer Epidemiol Biomarkers Prev, 23, 601-10. DOI |
18 | Maher SG, McDowell DT, Collins BC, et al (2011). Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg, 254, 809-16. DOI |
19 | Mandel JS, Church TR, Bond JH, et al (2000). The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Eng J Med, 343, 1603-7. DOI ScienceOn |
20 | Mehrabani D, Almasi-Hashiani A (2012a). Evaluation of the 5-year survival rate and demographic factors in colorectal cancer patients. Zanjan Med J, 20, 12-19. |
21 | Mehrabani D, Almasi-Hashiani A, Moshfeghi K, et al (2012b). Survival rate and its predictors in colorectal cancer patients, Southern Iran. Middle-East J Sci Res, 12, 1072-7. |
22 | Mehrabani D, Tabei SZ, Heydari ST, et al (2008). Cancer occurrence in Fars Province, Southern Iran. Iran Red Crescent Med J, 10, 314-22. |
23 | Miyazaki S, Kikuchi H, Iino I, et al (2014). Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int J Cancer, 135, 295-307. DOI |
24 | Pignone M, Rich M, Teutsch SM, et al (2002). Screening for colorectal cancer in adults at average risk: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med, 137, 132-41. DOI ScienceOn |
25 | Qian LY, Li P, Li XR, et al (2012). Multivariate analysis of molecular indicators for postoperative liver metastasis in colorectal cancer cases. Asian Pac J Cancer Prev, 13, 3967-71. 과학기술학회마을 DOI |
26 | Saberi-Firoozi M, Kamali D, Yousefi M, et al (2007). Clinical characteristics of colorectal cancer in Southern Iran, 2005. Iran Red Crescent Med J, 9, 209-11. |
27 | Safarpour AR, Hosseini SV, Mehrabani D (2013). Epidemiology of Inflammatory Bowel Diseases in Iran and Asia; A Mini Review. Iran J Med Sci, 38, 140-9. |
28 | Talaiezadeh A, Tabesh H, Sattari A, et al (2013). Cancer incidence in southwest of Iran: First report from Khuzestan population-based cancer registry, 2002-2009. Asian Pac J Cancer Prev, 14, 7517-22. 과학기술학회마을 DOI ScienceOn |
29 | Smith RA, Eschenbach AC, Wender R (2001). ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee: American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: Update 2001-testing for early lung cancer detection. CA Cancer J Clin, 51, 38-75. DOI ScienceOn |
30 | Szajewski M, Kruszewski WJ, Lakomy J (2014). VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma. Oncol Rep, 31, 125-30. |
31 | Wang Y, Han G, Wang K, et al (2014). Tumor-derived GM-CSF promotes inflammatory colon carcinogenesis via stimulating epithelial release of VEGF. Cancer Res, 74, 716-26. DOI |
32 | Ward DG, Suggett N, Cheng Y, et al (2006). Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer, 94, 1898-905. DOI ScienceOn |
33 | Winawer SJ, Flehinger BJ, Scholtenfeld D, et al (1993). Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst, 85, 1311-8. DOI ScienceOn |
34 | Yousefi AR, Karimi MH, Shamsdin SA, et al (2013). PD-1 Gene polymorphisms in Iranian patients with colorectal cancer. Lab Medicine, 44, 23-6. |
35 | Zubero MB, Arana-Arri E, Pijoan JI, et al (2014). Populationbased colorectal cancer screening: comparison of two fecal occult blood test. Front Pharmacol, 4, 175. |